| Peter Mazzone, MD | |
|
9500 Euclid Ave, Cleveland, OH 44195-0001 | |
| (800) 223-2273 | |
| Not Available |
| Full Name | Peter Mazzone |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 30 Years |
| Location | 9500 Euclid Ave, Cleveland, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033173554 | NPI | - | NPPES |
| 2261038 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 35072806M (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cleveland Clinic | Cleveland, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cleveland Clinic Foundation | 1850203555 | 5690 |
News Archive
The U.S. Food and Drug Administration today allowed marketing of the first test to help diagnose people with signs and symptoms of dengue fever or dengue hemorrhagic fever, a leading cause of illness and death in the tropics and subtropics.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today it has initiated dosing in a Phase I human clinical study with ALN-TTR01. The study is aimed at evaluating the safety and tolerability of ALN-TTR01 in patients with transthyretin -mediated amyloidosis, and is also designed to provide preliminary data on human proof of concept based on measurements of TTR serum levels.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported dosing of the first patient in the second of three planned Phase 3 studies that will form the basis of a planned New Drug Application for the Sufentanil NanoTab PCA System, ARX-01.
The National Institutes of Health have awarded, as part of the American Reinvestment and Recovery Act, a two-year, $2 million grant to a University of Georgia genetics researcher and her colleagues for studies on the thymus, the organ in humans that produces disease-fighting T-cells.
› Verified 4 days ago
| Entity Name | The Cleveland Clinic Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679525919 PECOS PAC ID: 1850203555 Enrollment ID: O20031103000049 |
News Archive
The U.S. Food and Drug Administration today allowed marketing of the first test to help diagnose people with signs and symptoms of dengue fever or dengue hemorrhagic fever, a leading cause of illness and death in the tropics and subtropics.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today it has initiated dosing in a Phase I human clinical study with ALN-TTR01. The study is aimed at evaluating the safety and tolerability of ALN-TTR01 in patients with transthyretin -mediated amyloidosis, and is also designed to provide preliminary data on human proof of concept based on measurements of TTR serum levels.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported dosing of the first patient in the second of three planned Phase 3 studies that will form the basis of a planned New Drug Application for the Sufentanil NanoTab PCA System, ARX-01.
The National Institutes of Health have awarded, as part of the American Reinvestment and Recovery Act, a two-year, $2 million grant to a University of Georgia genetics researcher and her colleagues for studies on the thymus, the organ in humans that produces disease-fighting T-cells.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Peter Mazzone, MD 6000 W Creek Rd, Suite 10, Independence, OH 44131-2139 Ph: (800) 223-2273 | Peter Mazzone, MD 9500 Euclid Ave, Cleveland, OH 44195-0001 Ph: (800) 223-2273 |
News Archive
The U.S. Food and Drug Administration today allowed marketing of the first test to help diagnose people with signs and symptoms of dengue fever or dengue hemorrhagic fever, a leading cause of illness and death in the tropics and subtropics.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today it has initiated dosing in a Phase I human clinical study with ALN-TTR01. The study is aimed at evaluating the safety and tolerability of ALN-TTR01 in patients with transthyretin -mediated amyloidosis, and is also designed to provide preliminary data on human proof of concept based on measurements of TTR serum levels.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported dosing of the first patient in the second of three planned Phase 3 studies that will form the basis of a planned New Drug Application for the Sufentanil NanoTab PCA System, ARX-01.
The National Institutes of Health have awarded, as part of the American Reinvestment and Recovery Act, a two-year, $2 million grant to a University of Georgia genetics researcher and her colleagues for studies on the thymus, the organ in humans that produces disease-fighting T-cells.
› Verified 4 days ago
Amir Razavi, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-7800 | |
Dr. Francois Fadell, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 18200 Lorain Ave, Moll Cancer Center At Fairview- Respiratory Institute, Cleveland, OH 44111 Phone: 216-444-6503 | |
Sana Hasan, DO Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195 Phone: 330-721-5700 | |
Catherine Frakes Vozzo, DO Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 9500 Euclid Ave, Cleveland, OH 44195 Phone: 216-444-4444 Fax: 216-445-6290 | |
Tarek Ashour, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 9500 Euclid Ave # Q7, Cleveland, OH 44195 Phone: 216-444-5040 | |
Mrs. Efewongbe Benedicta Oleghe, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2351 E 22nd Street, St Vincent's Charity Medical Center, Cleveland, OH 44115 Phone: 216-363-2725 | |
Dr. Toufik Z. Madhun, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 11100 Euclid Ave Dept Of, Cleveland, OH 44106 Phone: 216-844-1000 |